Fairpointe Capital’s Haemonetics HAE Stock Holding History

Fairpointe Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-59,700	Closed	-$2.36M	–	66
2017 Q2	$2.36M	Sell	59,700 -11,900	-17%	-$489K	0.05%	53
2017 Q1	$2.9M	Hold	71,600	–	–	0.06%	52
2016 Q4	$2.88M	Sell	71,600 -5,000	-7%	-$189K	0.06%	52
2016 Q3	$2.77M	Hold	76,600	–	–	0.06%	48
2016 Q2	$2.22M	Buy	76,600 +13,500	+21%	+$408K	0.05%	50
2016 Q1	$2.21M	Hold	63,100	–	–	0.05%	52
2015 Q4	$2.03M	Buy	63,100 +6,400	+11%	+$208K	0.04%	55
2015 Q3	$1.83M	Buy	56,700 +16,800	+42%	+$632K	0.03%	52
2015 Q2	$1.65M	Hold	39,900	–	–	0.02%	55
2015 Q1	$1.79M	Sell	39,900 -20,800	-34%	-$870K	0.02%	54
2014 Q4	$2.27M	Hold	60,700	–	–	0.03%	55
2014 Q3	$2.12M	Buy	+60,700	New	+$2.17M	0.03%	55

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fairpointe Capital's HAE Position: Q3 2017 in Review

Fairpointe Capital sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 59,700 shares — an estimated $2.36M sold.

Fairpointe Capital first reported a position in HAE in Q3 2014 and held it in 12 quarters. The position peaked at $2.9M in Q1 2017. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

Fairpointe Capital reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
Fairpointe Capital sold 59,700 Haemonetics shares in Q3 2017, an estimated $2.36M.
Fairpointe Capital first reported a position in Haemonetics in Q3 2014 and held it in 12 quarters.
Fairpointe Capital's Haemonetics position peaked at $2.9M in Q1 2017.
207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on Fairpointe Capital's 13F filing for Q3 2017, filed 14 Nov 2017.